Posts Tagged Jawbone

Wearable Technology (Focus in Healthcare track #TiEcon 2014)


Google and Apple have both fueled an ecosystem of apps for smartphones and tablets. Now Google has unveiled new software tools to help developers make apps for wearable devices.  So how big is the market potential for wearable devices?  According to Business Intelligence Research, wearables will transform the way we interact with our devices and they will become indispensable for monitoring body’s vital signs.  According to their conservative forecast, this may be a $12 Billion market.  Other estimates forecast the market for wearable computers to reach $20 billion in sales by 2016.

The vision of wearable sector is to interweave technology into everyday aspects of life.  Besides sports, athletics, and chronic disease monitoring, of particular interest is also the aging market.  Consider the US population demographics.  An American turns 50, every 7 seconds.  More people were 65+ in 2010 than in any previous censors.  As people age, there is greater likelihood of chronic diseases, falling, forgetting, medical adherence challenges and so on.  Also people prefer to live independently.  Wearable devices however, may not be panacea, if not designed and developed appropriately.  There are many challenges to developing these products.  Here is a link to my earlier post on “Challenges & Opportunities in Developing Products for Older Adults” – http://bit.ly/MqiC9E .

Healthcare system is undergoing a massive transformation.  Engaged consumers and better informed healthcare personnel will be an integral part of the new healthcare system.  Wearable computing devices will become absolutely necessary aspect of the changing healthcare landscape.  At Consumer Electronics Show (CES) in Las Vegas, wearables was one of the hottest sector.  While Fitbit, Basis, Jawbone, Pebble smart watches and Google Glass have been in the news, there are many werable devices in various stages of commercialization.  Innovators are working on putting sensors in socks, on wrists, in jewelry, even in a bra.  A new bra from a Japanese company Ravijour unhooks when you are in love (the embedded sensor analyzes the heart rate and springs open at the right moment).  But more importantly, a healthtech company, First Warning Systems, is getting ready to go into clinical trials with its wearable bra, designed to spot early signs of breast cancer.   

Indeed the future of wearable technology is a wide open landscape right now and much will be painted on it.  Healthcare track at TiEcon 2014 on May, 17 will focus on the future of wearable devices.  Register at www.tiecon.org.  Early bird price is available till midnight of March 10.

, , , , , , , , , , , , , , , , ,

Leave a comment

Crowdfunding – New Source of Capital for Medical Industry


Wilson, Sonsini, Goodrich, and Rosati 2013 Medical Device Conference (www.wsgr/news/medicaldevice.com) focused on understanding the challenges that Medtech startups encounter in the current environment, and the emerging strategies to respond to these challenges.  It was heavily attended by industry CEOs, venture capitalists, industry strategists, investment bankers, market analysts, and life science industry professionals.

Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati (Photo credit: Wikipedia)

Below are some highlights from panel on crowdfunding.  Crowdfunindg is emerging as a source of potential new source of capital for early stage and emerging growth companies.  The panel was moderated by Phil Oettinger, partner at WSGR and the panelists included Andrew Farquharson, Managing Director at InCube Ventures, Scott Jordan, Partner at S. Jordan Associates, Greg Shearer, Managing Director at Healthios, and Ben Lee, Director of Business Development at CircleUp.

Oettinger gave a background on Crowdfunding.  He also discussed impact of JOBS act that is expected to enable advertising for private investment offerings and allow unaccredited investors to participate in online equity crowdfunding.  Thus far, crowdfunding has not lived up to the hype of being a startup panacea.  It caps an amount an issuer can raise to $1M, in any 12-month period and caps the amount a person can invest in all crowdfundings over a one year period at 10% of annual income or net worth of the investor.  Shares issued in crowdfunding transactions are subject to a one-year restriction, and there are other restrictions that render non-US companies ineligible to participating in crowdfunding.  Crowdfunding also must be done through a registered broker-dealer or registered “funding portal”, who cannot solicit investments and law requires extensive due diligence, including background checks on management and large stockholders.  None of the challenges however, have dampened the enthusiasm.  SEC has already stated that equity crowdfunding portals are exempt from certain restrictions and more changes are on the way.

Scott Jordan is an accomplished life sciences business development and investment banking professional with over 20 years of corporate experience in negotiating strategic corporate alliances, securing international licensing agreements, building national sales teams, and contributing to successful product development, approval, and launch.  In partnership with Greg Shearer, Managing Director at Healthios Capital Markets, and CrowdConnect, Jordan and Associates, launched Healthios Xchange fund, with an aim to assist emerging growth healthcare companies raise capital from accredited investors, and non-dilutive financing from foundations.  It offers three large value propositions, said Shearer.  Open access eliminates selection bias and does not curate the deals going on the site.  “Crowd” anchors the continuum.  H/X scoring based on sophisticated algorithms, makes it heavily data centric, similar to LinkedIn.  Healthios charges fees to companies that raise money on its portal, except in certain cases where it offers carry-free, fee-free feature allowing investors an opportunity to directly invest in companies, eliminating transaction expenses.  The fees will likely fall in the 5-10% range.  The fee structure will be different for non-profits.  Each company gets a company pitch page.  Several features including e platform button, e signature of docs, e regulatory assessment etc., enhance ease of use.

Ben Lee, a developer of innovative teeth whitening products at GoSmile, and founder of TaskRabbit, an online services marketplace, joined CircleUp, which offers consumer companies an access to funding through passionate, sector focused investors.  “Very simply, crowdfunding is a numbers game and it offers an opportunity to reach out to large number of people, who are looking to invest”, said Lee.  CircleUp has launched a highly active, fast growing portal and has gained considerable credibility.  Lee said, “We are 100% focused on branded consumer products” where there is little institutional investment.

Prior to his current role at Incube Ventures, Andrew Farqharson, a serial entrepreneur had co-founded Operon with no venture capital and sold it for $150M.  He also had launched a company in microfludics, Innovadyne, and had held several roles in research operations at Genentech.  At InCube, with Mir Imran and Talat Imran, Farqharson co-founded VentureHealth, a crowdfunding portal, to enable physicians and other accredited investors to invest in “compelling biomedical inventions”.  Farqharson said, this emergence of crowdfunding is very exciting and enables entrepreneurs to be less dependent on VCs, while it unlocks a lot of latent capital, and also gives investors more degrees of freedom.  Unlike other equity crowdfunding portals on the panel, VentureHealth has adopted a carried-interest business model.  They do not charge fees to the companies that raise capital but charge the investors; just like a venture fund.  In this model being driven by carried interest, they make money only if their investors do.  Clearly, they have an incentive to only support the most promising companies, unlike many broker/dealer sites that may have lesser interest in screening for quality, as their primary incentive may be to raise capital for as many companies as they can.  It will be interesting to see which approach holds more long-term promise.  My initial thoughts are, if I, as a rather naive investor, were to risk my money, specifically in the complex class 2 and class 3 devices, with many regulatory, reimbursement, and marketing challenges, I would prefer to risk it where some prior due diligence is done by seasoned and serial entrepreneurs like Imrans and Farqharson.  Explaining the success of InCube Ventures, Farqharson said, despite the challenging environment, they have had 3 exits this year.  BodyMedia was acquired by Jawbone, NFocus Neuromedical was acquired by Covidien and most recently Spinal Modulation was acquired by St. Jude.  Exists led to $700M+ in 2013, said Farqharson. They are actively screening investors.

Image representing Spinal Modulation as depict...

Image via CrunchBase

 

 

Enhanced by Zemanta

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a comment

%d bloggers like this: